IHS Chemical Week

Regions :: India/Pakistan

Aurobindo Pharma’s API business reports rise in sales, targets annual API sales of $700 million by 2016

5:31 AM MDT | August 20, 2013 | Deepti Ramesh

The active pharmaceutical ingredients (API) business of Aurobindo Pharma (Hyderabad, India) reports a 10.2% rise in sales, to 6.46 billion Indian rupees ($101 million), in the fiscal first quarter, ended 30 June, compared with the year-ago quarter. Cephalosporin accounted for Rs2.16 billion of the total API sales in the first quarter, semisynthetic penicillin (SSP) accounted for Rs2.22 billion, and nonbetalactam accounted for Rs2.08 billion. Earnings figures for the API business have not been disclosed. Aurobindo Pharma manufactures generic pharmaceuticals...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa